Depomed (DEPO) Given Daily Media Impact Rating of 0.17

Media stories about Depomed (NASDAQ:DEPO) have trended somewhat positive recently, Accern Sentiment Analysis reports. Accern scores the sentiment of news coverage by reviewing more than 20 million news and blog sources. Accern ranks coverage of public companies on a scale of negative one to positive one, with scores nearest to one being the most favorable. Depomed earned a news impact score of 0.17 on Accern’s scale. Accern also gave media headlines about the specialty pharmaceutical company an impact score of 46.9649185862711 out of 100, meaning that recent news coverage is somewhat unlikely to have an impact on the stock’s share price in the next several days.

These are some of the media headlines that may have effected Accern Sentiment’s scoring:

Shares of Depomed (DEPO) traded down $0.21 during trading on Friday, reaching $6.81. The company had a trading volume of 1,579,013 shares, compared to its average volume of 1,317,086. Depomed has a 12 month low of $4.31 and a 12 month high of $16.09. The stock has a market cap of $431.75, a PE ratio of -4.18 and a beta of 1.10. The company has a quick ratio of 0.70, a current ratio of 0.74 and a debt-to-equity ratio of 3.21.

Depomed (NASDAQ:DEPO) last announced its earnings results on Tuesday, February 27th. The specialty pharmaceutical company reported $0.15 EPS for the quarter, beating analysts’ consensus estimates of $0.10 by $0.05. Depomed had a negative return on equity of 45.19% and a negative net margin of 26.92%. The company had revenue of $94.41 million during the quarter, compared to analysts’ expectations of $88.75 million. equities research analysts anticipate that Depomed will post -1.03 EPS for the current year.

A number of equities analysts have recently weighed in on DEPO shares. Mizuho upgraded Depomed from a “neutral” rating to a “buy” rating and set a $9.00 price target for the company in a report on Tuesday, December 5th. ValuEngine upgraded Depomed from a “strong sell” rating to a “sell” rating in a report on Tuesday, December 5th. BidaskClub upgraded Depomed from a “sell” rating to a “hold” rating in a report on Wednesday, December 6th. Piper Jaffray Companies reiterated a “hold” rating and set a $9.00 price target on shares of Depomed in a report on Thursday, December 7th. Finally, Royal Bank of Canada set a $9.00 target price on Depomed and gave the company a “hold” rating in a report on Thursday, December 7th. One analyst has rated the stock with a sell rating, seven have assigned a hold rating and three have issued a buy rating to the company’s stock. The stock has a consensus rating of “Hold” and a consensus target price of $9.56.

In related news, SVP Matthew M. Gosling sold 45,519 shares of the firm’s stock in a transaction dated Wednesday, March 7th. The stock was sold at an average price of $6.58, for a total transaction of $299,515.02. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Company insiders own 2.59% of the company’s stock.

TRADEMARK VIOLATION NOTICE: This news story was published by The Ledger Gazette and is the sole property of of The Ledger Gazette. If you are accessing this news story on another site, it was copied illegally and reposted in violation of United States and international copyright and trademark law. The correct version of this news story can be read at

Depomed Company Profile

Depomed, Inc is a specialty pharmaceutical company. The Company focuses on pain and other central nervous system (CNS) conditions. Its products include NUCYNTA ER (tapentadol extended release tablets), NUCYNTA IR (NUCYNTA) (tapentadol), Gralise (gabapentin), CAMBIA (diclofenac potassium for oral solution), Zipsor (diclofenac potassium) and Lazanda (fentanyl).

Insider Buying and Selling by Quarter for Depomed (NASDAQ:DEPO)

Receive News & Ratings for Depomed Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Depomed and related companies with's FREE daily email newsletter.

Leave a Reply